Has FDA Approved Ozempic for Weight Loss? Understanding the Facts

Last reviewed: June 9, 2026

Last updated: June 9, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

The Food and Drug Administration approved semaglutide for chronic weight management on June 4, 2021, under the brand name Wegovy. This milestone marked the first GLP-1 receptor agonist authorized for sustained weight loss in adults with a body mass index of 30 or higher, or 27 and above with at least one weight-related health condition. Understanding the difference between brand-name Ozempic and FDA-approved Wegovy, and how compounded alternatives fit into your weight loss journey, helps you make informed treatment decisions.

FDA Approval Timeline: Ozempic vs. Wegovy for Weight Loss

Ozempic is a branded semaglutide injection initially approved by the FDA in 2017 for type 2 diabetes management. The active compound—semaglutide—is identical in both formulations, but Ozempic carries a diabetes indication while Wegovy received specific FDA clearance for chronic weight management. This distinction matters because Ozempic is prescribed off-label for weight loss by many physicians, even though the FDA-approved weight loss indication belongs to Wegovy.

Wegovy's approval followed a pivotal 68-week clinical trial demonstrating that adults receiving semaglutide lost an average of 15% of their body weight compared to 2.4% in the placebo group. The trial enrolled over 1,600 participants and measured outcomes in people without type 2 diabetes, establishing the safety and efficacy profile specific to weight management rather than glucose control alone.

How Compounded Semaglutide Differs From Brand-Name Options

PlexusDx sources compounded semaglutide from licensed 503A compounding pharmacies, meaning the medication is prepared under strict pharmaceutical standards from FDA-approved raw materials. Compounded semaglutide contains the same active ingredient as Wegovy and Ozempic but is manufactured in a compounding setting rather than through commercial pharmaceutical plants. This allows PlexusDx to offer personalized dosing protocols without the markup of branded versions.

Brand-name Wegovy typically comes in pre-filled pens with fixed dose strengths (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg), whereas compounded semaglutide can be dosed more flexibly based on your individual tolerance and response. PlexusDx Compounded Semaglutide Injection is $189/mo month-to-month (or $149/mo on the 6-month plan), and your dose may need to go up—but your price won't. This flat-fee pricing model removes the financial barrier of escalating costs as your therapeutic dose increases.

Clinical Evidence Supporting Semaglutide for Sustained Weight Loss

Multiple large-scale trials have documented semaglutide's efficacy beyond the initial Wegovy approval study. The STEP trials (Semaglutide Treatment Effect in People with Obesity) enrolled over 4,500 participants across four studies, with results showing weight reductions of 10% to 17% depending on dose and trial duration. These findings established semaglutide as one of the most effective pharmacological interventions for chronic weight management available today.

Semaglutide works by activating GLP-1 receptors in the brain, which regulate appetite, satiety, and glucose metabolism. This mechanism differs from older weight loss medications that act primarily as stimulants; instead, semaglutide addresses the underlying hormonal drivers of obesity. Long-term follow-up data from STEP trials showed sustained weight loss for up to two years, with regain of only 4-6% of lost weight when patients continued treatment.

Personalized Dosing and Genetic Insights With PlexusDx

The PlexusDx Precision Peptide Genetic Test analyzes GIPR (rs1800437), FTO (rs9939609), and MC4R (rs17782313) — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to semaglutide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

The Precision Peptide Genetic Test is available for $298. Understanding your genetic peptide profile helps explain why some individuals respond dramatically to GLP-1 therapy while others need combination approaches or dosage adjustments. PlexusDx uses these insights to guide progression through microdose protocols, single compounds, or dual-compound therapies like GLP-Squared.

Access and Affordability: No Insurance Required

PlexusDx serves all 50 states with no insurance requirement, no membership fees, and full HSA/FSA eligibility. This direct-to-patient model removes insurance authorization delays and prior authorization denials that often prevent access to compounded semaglutide. Patients can begin treatment within days of their online consultation, with medications shipped directly to their home.

The pricing structure ensures transparency and predictability. Compounded Semaglutide Injection is $189/mo month-to-month (or $149/mo on the 6-month plan) across all three commitment tiers, meaning you know your cost upfront regardless of dose escalation. For those exploring alternatives, PlexusDx also offers Compounded Tirzepatide Injection (at $289/mo month-to-month, or from $249/mo on the 6-month plan), Oral Semaglutide ($289/mo), and combination therapies like GLP-Squared Injection ($289/mo), allowing you to find the formulation and active compound that fits your lifestyle and budget.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test ($298) to personalize your protocol from day one.

Frequently Asked Questions

Is Ozempic actually FDA approved for weight loss?

Ozempic itself is FDA-approved for type 2 diabetes, not weight loss. Wegovy—which contains the identical semaglutide molecule—received FDA approval specifically for chronic weight management in June 2021. Many physicians prescribe Ozempic off-label for weight loss, but the formal weight loss indication belongs to Wegovy. PlexusDx offers compounded semaglutide from licensed 503A pharmacies that provides the same active ingredient with flexible dosing.

How much weight can you expect to lose with semaglutide?

No — the Precision Peptide Genetic Test does not predict your response to Wegovy or any specific medication. It analyzes pathway-level variants (GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Why is PlexusDx compounded semaglutide more affordable than brand-name versions?

PlexusDx eliminates manufacturer markups and commercial distribution costs by sourcing from licensed 503A compounding pharmacies. Compounded Semaglutide Injection is $189/mo month-to-month (or $149/mo on the 6-month plan) with flat pricing across all dose levels—your dose may go up, but your price won't. Unlike brand-name Wegovy, which carries higher commercial overhead, PlexusDx passes savings directly to patients while maintaining pharmaceutical-grade quality and potency.

Are compounded semaglutide and Wegovy equally safe?

Compounded semaglutide from licensed 503A pharmacies contains the same FDA-approved active ingredient as Wegovy and Ozempic. All PlexusDx medications come from licensed compounders operating under strict USP standards for sterility, potency, and purity. Side effect profiles are identical because the active compound is identical; differences relate only to formulation source and delivery method, not safety or efficacy.

How does genetic testing improve my semaglutide treatment outcome?

No — the Precision Peptide Genetic Test does not predict your response to semaglutide or any specific medication. It analyzes pathway-level variants (GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Related Reading

• Ozempic For Weight Loss 2
• Average Weight Loss On Ozempic
• Weight Loss Drugs Like Ozempic
• Ozempic Weight Loss Before And After Pictures

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.